Águeda González-Rodríguez1,2, Beatriz Santamaría1,2, José Antonio Mas-Gutierrez3, Patricia Rada1,4, Elisa Fernández-Millán2,5, Virginia Pardo1,2, Carmen Álvarez2,5, Antonio Cuadrado1,4,6, Manuel Ros3, Manuel Serrano7, Ángela M Valverde1,2,6. 1. Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC/UAM), Madrid, Spain. 2. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), ISCIII, Spain. 3. Facultad de Ciencias, Universidad Rey Juan Carlos, Madrid, Spain. 4. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), ISCIII, Spain. 5. Departamento de Bioquímica y Biología Molecular II, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain. 6. Instituto de Investigacion Sanitaria La Paz (IdiPaz), Madrid, Spain. 7. Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Abstract
SCOPE: Mice with deletion of insulin receptor substrate (IRS) 2 develop hyperglycaemia, impaired hepatic insulin signaling and elevated gluconeogenesis. Protein tyrosine phosphatase 1B (PTP1B) inhibition by resveratrol improves peripheral insulin sensitivity of these mice. Although resveratrol activates Sirtuin1 (Sirt1), the mechanisms underlying its beneficial effects are not totally elucidated. In this study, we have investigated whether Sirt1 mediates the effects of resveratrol in controlling insulin resistance in diabetic mice. METHODS AND RESULTS: We attempted to ameliorate peripheral insulin resistance in two diabetic models, Irs2-deficient (Irs2(-/-)) mice and streptozotocin (STZ)-injected mice by resveratrol treatment or Sirt1 overexpression. Resveratrol improved systemic insulin sensitivity of Irs2-deficient mice. Irs2-deficient mice are characterized by high levels of PTP1B expression in liver and muscle. Interestingly, resveratrol decreased PTP1B in both tissues, thereby restoring IRS1-mediated insulin signaling. Moreover, resveratrol also restored insulin sensitivity and hepatic insulin signaling in STZ-diabetic mice. In contrast, moderate overexpression of Sirt1 neither normalized PTP1B levels nor restored insulin signaling in Irs2-deficient mice or STZ-diabetic mice. CONCLUSION: Resveratrol improves peripheral insulin signaling independently of Sirt1 in diabetic mice in association with the inhibition of PTP1B and, therefore, this polyphenol could be an effective adjuvant for the treatment of diabetes.
SCOPE: Mice with deletion of insulin receptor substrate (IRS) 2 develop hyperglycaemia, impaired hepatic insulin signaling and elevated gluconeogenesis. Protein tyrosine phosphatase 1B (PTP1B) inhibition by resveratrol improves peripheral insulin sensitivity of these mice. Although resveratrol activates Sirtuin1 (Sirt1), the mechanisms underlying its beneficial effects are not totally elucidated. In this study, we have investigated whether Sirt1 mediates the effects of resveratrol in controlling insulin resistance in diabeticmice. METHODS AND RESULTS: We attempted to ameliorate peripheral insulin resistance in two diabetic models, Irs2-deficient (Irs2(-/-)) mice and streptozotocin (STZ)-injected mice by resveratrol treatment or Sirt1 overexpression. Resveratrol improved systemic insulin sensitivity of Irs2-deficientmice. Irs2-deficientmice are characterized by high levels of PTP1B expression in liver and muscle. Interestingly, resveratrol decreased PTP1B in both tissues, thereby restoring IRS1-mediated insulin signaling. Moreover, resveratrol also restored insulin sensitivity and hepatic insulin signaling in STZ-diabeticmice. In contrast, moderate overexpression of Sirt1 neither normalized PTP1B levels nor restored insulin signaling in Irs2-deficientmice or STZ-diabeticmice. CONCLUSION:Resveratrol improves peripheral insulin signaling independently of Sirt1 in diabeticmice in association with the inhibition of PTP1B and, therefore, this polyphenol could be an effective adjuvant for the treatment of diabetes.
Authors: Ruben Grillo-Risco; Laura Pereira; M Carmen Soler-Vázquez; Inés Barahona; Patricia Rada; Silvia Calero-Pérez; Laura María LaIglesia; María J Moreno-Aliaga; Laura Herrero; Dolors Serra; Carmelo García-Monzon; Águeda González-Rodriguez; Jesús Balsinde; Francisco García-García; M Pilar Valdecantos; Ángela M Valverde Journal: Cell Death Differ Date: 2022-06-09 Impact factor: 15.828
Authors: Patricia Rada; Virginia Pardo; Maysa A Mobasher; Irma García-Martínez; Laura Ruiz; Águeda González-Rodríguez; Cristina Sanchez-Ramos; Jordi Muntané; Susana Alemany; Laura P James; Kenneth J Simpson; María Monsalve; Maria Pilar Valdecantos; Ángela M Valverde Journal: Antioxid Redox Signal Date: 2017-12-11 Impact factor: 7.468